115 related articles for article (PubMed ID: 22266152)
1. Autoimmunity, intestinal lymphoid hyperplasia, and defects in mucosal B-cell homeostasis in patients with PTEN hamartoma tumor syndrome.
Heindl M; Händel N; Ngeow J; Kionke J; Wittekind C; Kamprad M; Rensing-Ehl A; Ehl S; Reifenberger J; Loddenkemper C; Maul J; Hoffmeister A; Aretz S; Kiess W; Eng C; Uhlig HH
Gastroenterology; 2012 May; 142(5):1093-1096.e6. PubMed ID: 22266152
[TBL] [Abstract][Full Text] [Related]
2. Immune dysregulation in patients with PTEN hamartoma tumor syndrome: Analysis of FOXP3 regulatory T cells.
Chen HH; Händel N; Ngeow J; Muller J; Hühn M; Yang HT; Heindl M; Berbers RM; Hegazy AN; Kionke J; Yehia L; Sack U; Bläser F; Rensing-Ehl A; Reifenberger J; Keith J; Travis S; Merkenschlager A; Kiess W; Wittekind C; Walker L; Ehl S; Aretz S; Dustin ML; Eng C; Powrie F; Uhlig HH
J Allergy Clin Immunol; 2017 Feb; 139(2):607-620.e15. PubMed ID: 27477328
[TBL] [Abstract][Full Text] [Related]
3. Phosphatase and tensin homolog (PTEN) mutation can cause activated phosphatidylinositol 3-kinase δ syndrome-like immunodeficiency.
Tsujita Y; Mitsui-Sekinaka K; Imai K; Yeh TW; Mitsuiki N; Asano T; Ohnishi H; Kato Z; Sekinaka Y; Zaha K; Kato T; Okano T; Takashima T; Kobayashi K; Kimura M; Kunitsu T; Maruo Y; Kanegane H; Takagi M; Yoshida K; Okuno Y; Muramatsu H; Shiraishi Y; Chiba K; Tanaka H; Miyano S; Kojima S; Ogawa S; Ohara O; Okada S; Kobayashi M; Morio T; Nonoyama S
J Allergy Clin Immunol; 2016 Dec; 138(6):1672-1680.e10. PubMed ID: 27426521
[TBL] [Abstract][Full Text] [Related]
4. Activation of PI3K/Akt/mTOR signaling pathway triggered by PTEN downregulation in the pathogenesis of Crohn's disease.
Long SH; He Y; Chen MH; Cao K; Chen YJ; Chen BL; Mao R; Zhang SH; Zhu ZH; Zeng ZR; Hu PJ
J Dig Dis; 2013 Dec; 14(12):662-9. PubMed ID: 23962154
[TBL] [Abstract][Full Text] [Related]
5. The Role of PTEN in Innate and Adaptive Immunity.
Taylor H; Laurence ADJ; Uhlig HH
Cold Spring Harb Perspect Med; 2019 Dec; 9(12):. PubMed ID: 31501268
[TBL] [Abstract][Full Text] [Related]
6. Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway.
Martelli AM; Evangelisti C; Chappell W; Abrams SL; Bäsecke J; Stivala F; Donia M; Fagone P; Nicoletti F; Libra M; Ruvolo V; Ruvolo P; Kempf CR; Steelman LS; McCubrey JA
Leukemia; 2011 Jul; 25(7):1064-79. PubMed ID: 21436840
[TBL] [Abstract][Full Text] [Related]
7. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.
McCubrey JA; Steelman LS; Abrams SL; Lee JT; Chang F; Bertrand FE; Navolanic PM; Terrian DM; Franklin RA; D'Assoro AB; Salisbury JL; Mazzarino MC; Stivala F; Libra M
Adv Enzyme Regul; 2006; 46():249-79. PubMed ID: 16854453
[TBL] [Abstract][Full Text] [Related]
8. Primary lung adenocarcinoma occurring in a PTEN related syndrome (Cowden's disease): routine EGFR sequencing also highlights two rare somatic mutations S768I and V769L.
Boespflug A; Couraud S; Bringuier PP; Isaac S; Gérinière L; Perrot E; Edery P; Durieu I; Souquet PJ
Lung Cancer; 2013 Mar; 79(3):318-20. PubMed ID: 23261230
[TBL] [Abstract][Full Text] [Related]
9. Sirolimus treatment of severe PTEN hamartoma tumor syndrome: case report and in vitro studies.
Schmid GL; Kässner F; Uhlig HH; Körner A; Kratzsch J; Händel N; Zepp FP; Kowalzik F; Laner A; Starke S; Wilhelm FK; Schuster S; Viehweger A; Hirsch W; Kiess W; Garten A
Pediatr Res; 2014 Apr; 75(4):527-34. PubMed ID: 24366516
[TBL] [Abstract][Full Text] [Related]
10. [Dermatological implications of the PI3K pathway].
Dereure O
Ann Dermatol Venereol; 2015 Oct; 142(10):622-3. PubMed ID: 26001484
[No Abstract] [Full Text] [Related]
11. Modulation of epithelial neoplasia and lymphoid hyperplasia in PTEN+/- mice by the p85 regulatory subunits of phosphoinositide 3-kinase.
Luo J; Sobkiw CL; Logsdon NM; Watt JM; Signoretti S; O'Connell F; Shin E; Shim Y; Pao L; Neel BG; Depinho RA; Loda M; Cantley LC
Proc Natl Acad Sci U S A; 2005 Jul; 102(29):10238-43. PubMed ID: 16006513
[TBL] [Abstract][Full Text] [Related]
12. PTEN, more than the AKT pathway.
Blanco-Aparicio C; Renner O; Leal JF; Carnero A
Carcinogenesis; 2007 Jul; 28(7):1379-86. PubMed ID: 17341655
[TBL] [Abstract][Full Text] [Related]
13. A detailed immunohistochemical analysis of the PI3K/AKT/mTOR pathway in lung cancer: correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features.
Trigka EA; Levidou G; Saetta AA; Chatziandreou I; Tomos P; Thalassinos N; Anastasiou N; Spartalis E; Kavantzas N; Patsouris E; Korkolopoulou P
Oncol Rep; 2013 Aug; 30(2):623-36. PubMed ID: 23728071
[TBL] [Abstract][Full Text] [Related]
14. Beta catenin and cytokine pathway dysregulation in patients with manifestations of the "PTEN hamartoma tumor syndrome".
Galatola M; Paparo L; Duraturo F; Turano M; Rossi GB; Izzo P; De Rosa M
BMC Med Genet; 2012 Apr; 13():28. PubMed ID: 22520842
[TBL] [Abstract][Full Text] [Related]
15. Germline PTEN mutations are associated with a skewed peripheral immune repertoire in humans and mice.
Jaini R; Loya MG; King AT; Thacker S; Sarn NB; Yu Q; Stark GR; Eng C
Hum Mol Genet; 2020 Aug; 29(14):2353-2364. PubMed ID: 32588888
[TBL] [Abstract][Full Text] [Related]
16. E-cadherin inhibits tumor cell growth by suppressing PI3K/Akt signaling via β-catenin-Egr1-mediated PTEN expression.
Lau MT; Klausen C; Leung PC
Oncogene; 2011 Jun; 30(24):2753-66. PubMed ID: 21297666
[TBL] [Abstract][Full Text] [Related]
17. Reconstitution of the mammalian PI3K/PTEN/Akt pathway in yeast.
Rodríguez-Escudero I; Roelants FM; Thorner J; Nombela C; Molina M; Cid VJ
Biochem J; 2005 Sep; 390(Pt 2):613-23. PubMed ID: 15913452
[TBL] [Abstract][Full Text] [Related]
18. Molecular aspects of gefitinib antiproliferative and pro-apoptotic effects in PTEN-positive and PTEN-negative prostate cancer cell lines.
Festuccia C; Muzi P; Millimaggi D; Biordi L; Gravina GL; Speca S; Angelucci A; Dolo V; Vicentini C; Bologna M
Endocr Relat Cancer; 2005 Dec; 12(4):983-98. PubMed ID: 16322337
[TBL] [Abstract][Full Text] [Related]
19. PI3K/AKT pathway activation in bladder carcinogenesis.
Calderaro J; Rebouissou S; de Koning L; Masmoudi A; Hérault A; Dubois T; Maille P; Soyeux P; Sibony M; de la Taille A; Vordos D; Lebret T; Radvanyi F; Allory Y
Int J Cancer; 2014 Apr; 134(8):1776-84. PubMed ID: 24122582
[TBL] [Abstract][Full Text] [Related]
20. Expression and alterations of the PTEN / AKT / mTOR pathway in ameloblastomas.
Scheper MA; Chaisuparat R; Nikitakis NG; Sauk JJ
Oral Dis; 2008 Sep; 14(6):561-8. PubMed ID: 18826385
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]